ABSTRACT. Twenty-four growth hormone-deficient children were treated with growth hormone releasing hormone-40 (GHRH) for 6 months or longer. GHRH (1 to 4 pg/kg of body weight per dose) was administered subcutaneously every 3 h (n = 10); or every 3 h overnight only (n = 10); or by twice daily injections (n = 4). Twenty-one children had an increase in growth rate during GHRH treatment. The growth velocities (mean f SD; cmlyr) before and during treatment were, respectively: every 3 h 3.5 f 1.4 versus 10.0 f 2.2, p = 0.0001; overnight only 3.4 f 1.0 versus 6.2 f 2.1, p = 0.008; twice daily injections 3.2 f 1.8 versus 7.9 f 2.4, p = 0.06. Using these three modes of GHRH administration, different total daily amounts of GHRH were administered. Regression analysis of average daily dose versus growth velocity revealed a correlation coefficient (r) value of 0.57, p = 0.004. Sixteen children received extendeti treatment for periods varying from 9 to 30 months. Of these, seven children were treated continuously for 9 months with pump overnight only and 5 for 12 months with pump every 3 h. Their growth velocities were sustained at a similar rate as those observed at 6 months. Six children received both twice daily and three hourly treatments consecutively. The growth velocities were similar during both treatments. Eleven children developed circulating antibodies to GHRH during treatment, however, all 11 had accelerated growth rates during GHRH therapy. GHRH can stimulate growth hormone secretion and its biologic effects to accelerate linear growth in children with growth hormone deficiency. Further studies are required to characterize the optimal dose and frequency of administration. (Pediatr Res 24: 145-151, 1988)
The majority of GH-deficient children with short stature and growth failure have a disorder of hypothalamic regulation of the anterior pituitary rather than a defect of the somatotrope. In these children single injections of GHRH may stimulate GH secretion. We have previously reported preliminary results of GHRH therapy in seven GH-deficient children (1-3) and now report a multicenter trial of this therapy in 24 patients treated for 6 months or more.
METHODS
Twenty-four children with short stature, growth failure, and GH deficiency secondary to idiopathic or organic hypopituitarism were enrolled in the study after they assented and their parents gave written informed consent. The study was approved by the Human Investigation Committees of the University of Virginia, the Salk Institute, The Middlesex Hospital, the University of Colorado School of Medicine, Vanderbilt School of Medicine, and Tufts New England Medical Center, and by the United States Food and Drug Administration. Each child was admitted to the respective center before starting the study and underwent a physical examination with special emphasis on growth characteristics and assessment of his/her endocrine function, including standard test(s) of growth hormone reserve: levo-dopa, 7 mg/ kg of body weight, by mouth, and arginine, 0.5 g/kg by intravenous infusion over a 30-min period; and/or insulin-induced hypoglycemia, 0.075 to 0.1 U/kg, intravenously; or clonidine, 0.15 mg/m2 and insulin, 0.1 U/kg. In addition, radiologic examination included determination of bone age (4, 5) and high resolution CT scanning of the head. The criteria for admission into the protocol included observation of the child for at least 6 months to document that: I) the growth velocity was less than 5 cm/yr, 2) the child was prepubertal, and 3) peak GH concentraAbbreviations tions after pharmacologic test(s) were less than 10 ng/ml. All GHRH, growth hormone-releasing hormone children had a GH response to GHRH with a minimum peak of GH, growth hormone 3.2 ng/ml (range of 3.2-106.9 ng/ml). Three children had been hGH, human growth hormone previously treated with growth hormone (no. 2 for 1.2-yr, no. 7 for 0.5 yr, and no. 9 for 3.6 yr). hGH treatment was discontinued
Received December 22, 1987; accepted March 15, 1988. at least 6 months before entry into the study. The children were seen at a minimum of 4-wk intervals at which time a blood sample was drawn for measurement of somatomedin C concentration and for the presence of anti-GHRH antibody. In addition, height was measured every 4 wk upon arising in the morning by a single observer using a Harpenden stadiometer. Immediately before starting treatment and after 6 months of therapy each child underwent a test with GHRH, 1 pg/kg as an intravenous bolus; this was performed at the same time of day on each occasion 3 h after the previous subcutaneous dose.
Serum growth hormone, somatomedin C, thyrotropin, and thyroxine concentrations were measured either by radioimmunoassay as previously described (1, 3) or by immunoradiometric assay (GH) using reagents purchased from Nichols Institute (San Juan Capistrano, CA). The sensitivity of the latter GH assay is 0.5 ng/ml and the inter-and intraassay coefficients of variability at 4.5 ng/ml were 7.1 and 5.5%. The sera collected to determine if antibodies to GHRH had developed were examined at final concentrations of 1 :50, 1 : 100, 1 :500, and 1 : 1000. Antibody bound [1251]-GHRH(l-40)-OH was separated from free tracer by goat anti-human y-globulin (Scantibodies, lot no. R496F). As a control for the quality of the tracer, it was tested with rabbit antihuman GHRH(1-40)-OH (7Q) and bound 40% at 1:200,000. Antibodies to GHRH were considered to be present when GHRH binding was >2-fold nonspecific binding (1, 2) .
Analysis. Absolute growth velocities after 6 months and 9 months of treatment and the incremental growth velocities (the change in growth from pretreatment to 6 or 9 months of treatment) were compared. An increment or change in growth velocity of 2 1.8 cm/yr was arbitrarily considered a significant response to GHRH therapy inasmuch as it is outside the random measurement error for consecutive measurements over a 6-month period. Analysis of variance was used to compare the results of three treatment regimens. The Student's t test was used for all other analyses. A p values of 50.05 was considered significant. Linear regression analysis was used to identify the strength of the relationship between the average daily dose (pglkglday) and increase in growth rates.
Patients treated. Preliminary results of seven of these children were previously reported, but their extended treatment periods are included to give a more complete overview (1-3). Details of pretreatment evaluation of each child are shown in Appendix Tables 1-3 in appendix and are listed by initial therapy. The peak GH response to any of the two or more pharmacologic tests of GH reserve is shown. Twenty of the children had idiopathic GH deficiency and four had organic causes-idiopathic hydrocephalus, septo-optic dysplasia, posttraumatic, and subarachoid suprasellar cyst with hydrocephalus. One patient who entered the study is not included because of poor compliance with therapy. All children fulfilled the criteria for growth retardation secondary to GH deficiency including short stature and subnormal growth velocity. The bone age was retarded when compared to the chronologic age, (mean f SD) 6.1 f 2.6 yr bone age versus 9.3 k 2.5 yr chronologic age, p < 0.0001. The peak growth hormone concentration after a pharmacologic test was 5 10 ng/ ml. In every child tested the peak GH response to GHRH was greater than to the pharmalogic test(s). The mean (+ SD; ng/ml) after GHRH was 27.6 + 23.9 versus 3.3 k 2.5 after pharmacologic test, p < 0.000 I, n = 23. Analysis of variance demonstrated no significant differences in the pretreatment measurements among the three treatment groups.
RESULTS

GROWTH VELOCITY
Initial 6 Months. GHRH treatment administered by pump every 3 h. Ten children were treated with GHRH by pump every 3 h for six months. A dose of 1 pg/kg/pulse was given to five children and increased to 3 pg/kg/pulse in two. Five children were treated with a dose of 2 pg/kg/per pulse throughout (Fig. 1, left) .
The growth velocity (mean f SD; cm/yr) before treatment was 3.5 + 1.4 versus 10.0 f 2.2 at the end of treatment, p = 0.000 1. All children grew at an accelerated velocity ranging from 7.1 to 14.1 cm/yr during treatment. The increase in growth velocity (mean f SD) was 6.5 f 2.5 cm/year. 3 h; overnight only. Five children were treated at a dose of 1 pg/kg/pulse for 12 wk after which the dose was doubled. An additional five children were treated throughout with 2 pglkglpulse (Fig. 1 , middle).
GHRH treatment administered by pump every
The growth velocity (mean f SD; cm/yr) before treatment was 3.4 f 1.0 versus 6.2 + 2.1 at the end of treatment, p = 0.008.
Seven of the 10 patients grew at an accelerated velocity ranging from 5.0 to 8.9 cm/yr during treatment, however, two subjects (nos. 13 and 15) had a decrease in their growth velocities (from 4.8 to 3.4 and from 4.2 to 3.8, respectively). One subject (no. 16) showed an increase of only 1.4 cm/yr (from 3.3 to 4.7 cm/ yr).
GHRH treatment administered by twice daily injections. Four children were treated for six months with twice daily injections of GHRH, 4 pg/kg/dose (Fig. 1, right) .
The pretreatment growth velocity (mean f SD; cm/yr) was 3.2 f 1.8 versus 7.9 f 2.4 during treatment, p = 0.06. All four grew at an accelerated velocity ranging from 6.1 to 11.4 cm/yr on therapy. The increase in growth velocity (mean f SD) was 4.8 f 3.2 cm/yr.
Comparison of absolute and incremental growth velocities (mean f SD; cmlyr) of three different regimens over 6 months.
The three treatment groups were comparable in terms of pretreatment chronologic age, bone age, peak GH response to pharmacologic test(s) and to GHRH (Appendix Tables 1-3 ).
The absolute growth velocity and the incremental growth velocity were greatest for GHRH administered every 3 h, when compared with GHRH administered every 3 h overnight only. The mean ( f SD) absolute growth velocity (pump every 3 h versus pump overnight) was 10.0 f 2.2 versus 6.2 f 2.1 and the mean ( f SD) incremental growth velocity was 6.5 5 Figure 2 . All children had an accelerated growth rate. One child (no. 5) had treatment extended to 18 months. Her growth velocities before, at 6, 9, 12, and 18 months were 3.5, 10.9, 9.6, 9.0, and 9.1 cm/yr. At 12 months she was prepubertal and by 18 months she had Tanner stage I1 breast development (6, 7).
The mean growth velocities of these five children (mean + SD; cm/yr) before, at 6, 9, and 12 months were 3.6 f 1.7, 10.7 f 1.4, 9.4 + 1.4, and 8.6 + 1.2, respectively, and were all significantly different from the pretreatment growth velocities and from each other, p < 0.002.
GHRH treatment administered every 3 h; overnight only.
Treatment was extended to 9 months in seven of 10 children. Their growth velocities before, at 6 and 9 months are shown individually in Figure 3 . The mean growth (mean + SD; cm/yr) before and at 6 and 9 months were 3.4 + 0. patients had a greater response to the GHRH intravenous bolus injection at the end of the first 6 months of treatment compared with the pretreatment response. The response in nine patients was the same or was lower. The mean response for the group did not differ from pretherapy to that after 6 months of treatment.
Somatomedin C and alkaline phosphatase concentrations. The somatomedin C concentrations for the 17 patients in whom both baseline and 6 months samples were available are summarized in Table 2 . The pretreatment values did not differ among therapeutic groups. Similarly, the maximal somatomedin C concentrations measured during therapy and after 6 months of therapy did not differ significantly among groups. The mean (+ SD) somatomedin C concentration increased from a pretreatment value of 0.22 + 0.24 to 0.30 f 0.27 U/ml after 6 months, p < 0.05. Wide fluctuations in somatomedin C levels were observed during treatment and the mean maximal somatomedin C concentration for the group (0.40 + 0.30 U/ml) was significantly increased from the pretreatment value, p < 0.01. The alkaline phosphatase concentrations did not vary with treatment (data not shown).
Antibody development. Eleven children developed circulating
antibodies to GHRH at <1:500 dilution during therapy. However, all l l had accelerated growth rates during GHRH therapy. Nine children treated with GHRH by pump developed low titer antibodies to GHRH, although in one (no. 7) the antibody concentration was detected only after the change to twice daily injections. One of four subjects treated initially with twice daily injections developed antibodies. Antibody titers were below the level of detectability (1:50) in 10 of the 1 1 children either during continuation of treatment (three patients) or after stopping treatment.
DISCUSSION
Once GHRH was isolated, characterized, and synthesized in 1982, its role as a therapeutic agent for treatment of G H deficiency needed to be established. Our preliminary studies of GHRH therapy in which two and five children, respectively, had an acceleration of growth velocity during intermittent pulsatile 1-3) . Similarly, other investigators reported that administration of GHRH by once or twice daily injections or by pump resulted in acceleration of growth velocity (8-1 0). This study was designed to evaluate efficacy of GHRH therapy in a larger number of patients during three different treatment regimens that used a variety of doses. These results are pooled data from a collaborative study at five hospitals and demonstrate that GHRH therapy was effective in promoting acceleration of growth velocity in 2 1 of 24 GH-deficient children (88%). The three children who did not respond received GHRH administered by pump overnight only (with the lowest average dose of 6 or 8 pglkglday) and who therefore received only half of the dose compared with children treated by pump throughout the 24-h period.
Acceleration of growth velocity was achieved by administering GHRH either by pump every 3 h over a 24-h period, every 3 h overnight only or by twice daily injections. The best results occurred when GHRH was given every 3 h by pump over a 24-h period; these children also received a larger daily dose than did the others. The average (mean + SD; pg/kg/day) doses administered during the three regimens were 14.2 + 4.4 (pump over a 24-h period), 7.0 f 1.1 (pump overnight only), and 8.0 (twice daily injections). Inasmuch as the same doses were not administered during each treatment regimen, it is not possible to determine if GHRH administration every 3 h by pump is more eficacious than the other regimens. However, results of the regression analysis that correlate average daily dose with growth velocity suggest that the total daily dose is of critical importance.
We initially proposed that stimulation of the somatotrope every 3 h with GHRH would mimic the normal G H secretory pattern and thus promote growth (I). Evidence supporting this hypothesis carne from the studies by Clark et al. (1 1) who reported that rats given G H by continuous infusion did not grow as well as when the same dose was given intravenously every 3 h. However, observations that administration of pharmacologic doses of hGH to GH-deficient children three times weekly promotes growth acceleration suggest that the frequency of administration may not be the most important factor. Whether GHRH is equivalent, inferior, or superior to hGH treatment of GHdeficient children is an important practical question that was not addressed in this study. The goal of this study was to determine if a large number of GH-deficient children would respond to GHRH and, if possible, to determine the optimal dose and frequency of administration. The maximal growth rate occurred after 6 months of therapy when GHRH was administered by pump over a 24-h period. The growth velocity declined slightly over the next 6 months. These observations are similar to the pattern of growth observed in GH-deficient children treated with pituitary-derived and recombinant hGH (12, 13) . It should be noted that the mean (+ SD) increase in growth velocity during the first 12 months of hGH therapy was 10.5 f 2.2 cm/yr (13) when a dose of 0.1 mg/kg of methionyl-hGH or pituitary hGH (Kabi Vitrum AB, Stockholm, Sweden) was given three times a week. This is a larger dose than that used in earlier studies of pituitary-derived hGH. The growth velocity achieved during hGH therapy is similar to the mean (f. SD) growth velocity achieved during the first 6 months of GHRH administration by pump every 3 h of 10.0 k 2.2 cm/yr (range of 7.1-14.1 cm/yr). In children treated with GHRH for more than 6 months, accelerated growth was sustained for 1 yr or longer. Inasmuch as the majority of patients had a good response to GHRH treatment, it is now feasible to perform a controlled study to compare the effects of GHRH and hGH therapy. It appears that GHRH is effective when given once daily (8) . Therefore, the continued use of pump administration may now be an academic rather than practical consideration. In our study where patients and their parents were carefully selected, use of the pump did not present a major problem. The GH response to an intravenous dose of GHRH did not increase after 6 months of treatment and this is not altogether surprising for several reasons. The response to GHRH is variable in normal subjects and GH-deficient patients. Additionally, variable response to GHRH occurs when the same subject is given a dose on different days. All patients had a brisk GH response to GHRH before the initiation of therapy which suggests that the somatotrope did not require "priming." Furthermore, the intravenous dose used was a maximal dose, and a change in sensitivity to GHRH would likely not be detectable.
A modest increase in serum somatomedin C concentrations was observed after 6 months of GHRH therapy. This was somewhat surprising inasmuch as a large increase was observed during short-term GHRH therapy and in the two previously reported patients (1, 14) . The reason for this difference is not known. Wide fluctuations in serum somatomedin C levels were observed during therapy and the mean maximal level was significantly increased compared with the mean pretreatment level. This lack of correlation between somatomedin C levels and growth rate has also been observed in children treated with hGH (1 5). These findings support the hypothesis that somatomedin C has an autocrine or paracrine function and that local somatomedin production by peripheral tissues, e.g. epiphyseal plate, and not the circulating homone concentration, is most important for stimulating linear growth.
Antibodies to GHRH developed in 11 of 24 patients. The clinical significance of these antibodies is unknown because growth acceleration and the GH response to intravenous GHRH were maintained. The antibody titers decreased in all children either during continued GHRH therapy or after discontinuation of treatment. Other investigators have reported development of anti-GHRH antibodies that were not associated with failure to respond to therapy (8, 9) .
Our results are in agreement with those of Low et al. (10) who treated seven GH-deficient children with GHRH by pump for 12 months and with the only other 1-yr study published in which GHRH was administered once daily (10 pg/kg/day) (8). However, our results differ in several important respects from the only other large published series (9). Ross et al. (9) selected a different population of GH-deficient children, most of whom had been treated with hGH within the preceding 3 to 6 months. Only three of the 24 patients in our study had received hGH that was discontinued for at least 6 months before GHRH treatment. An equipotent GHRH analog was used and the dose range was higher, 25-50 pg/kg/day. The maximum dose in our study was 19 pg/kg/day. Despite the larger GHRH doses used by Ross et al. (9) , only eight of 18 patients had accelerated growth after 6 months of treatment. During prior hGH therapy, the "nonresponders" had lower growth rates than did the "responders." There was little. if anv. "catch down growth" after withdrawal of hGH therapy which suggests that these nonresponders may have had incomplete GH deficiency. The dose of GHRH is unlikely to account for the lower incidence of accelerated growth in the study by Ross et al. (9) because they used a higher dose than was used in our study. However, there is no information on bioavailability of the GHRH analog which may also influence efficacy. Some major questions remain, including whether optimal growth is maintained during stimulation of pulsatile G H secretion. If this concept is correct, then repeated administration of GHRH or use of a sustained-release GHRH preparation is a feasible method of therapy to maintain pulsatile G H secretion. To date, there appears to be minimal toxicity with the exception of development of antibodies to GHRH, which appears to be of little practical importance. The cost of hGH or GHRH depends on manufacturing and development costs and on market forces. If GHRH is to succeed as an alternative to hGH, it must be at least as efficacious, be more convenient to administer, and less costly than hGH.
In summary, this multicenter study demonstrates that GHRH therapy is effective in accelerating growth in GH-deficient children. The results suggest that a dose of at least 8 pg/kg/day (i.e. 1 pg/kg/dose every 3 h or 4 pg/kg b.i.d.) is required. Additionally, administration of 1 pg/kg/dose every 3 h overnight only did not promote the same growth response as when GHRH was administered every 3 h throughout the 24-h period. The optimal mode of therapy, whether pulsatile or by once or twice daily subcutaneous injections, needs to be determined and a dose-response study with a fixed regimen is necessary. There are theoretical reasons and preliminary data to suggest that a sustained release GHRH preparation may be effective in restoring pulsatile G H secretion and consequent growth acceleration in GH-deficient children ( 16) . 11 Insulin/clonidine.
APPENDIX
